Fig. 1

Immunogenic cell death-activated and cDC1-mediated anticancer immunity. ICD-inducing therapies have the ability to stimulate the antigenicity and adjuvanticity of malignant cells, via a viral mimicry that facilitates the emission of danger associated molecular patterns (DAMP) by the cancer cells which in turn lead to the recruitment and activation of professional antigen-presenting cDC1 dendritic cells into the tumor bed. Activated mature cDC1s can migrate to tertiary lymphoid structures or to draining lymph nodes for the education of cytotoxic T lymphocytes (CTL) that then engage in the destruction of residual or distant cancer cells (Created with BioRender.com)